William Cook

Summary

Affiliation: AstraZeneca R and D

Publications

  1. ncbi request reprint Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials
    William Cook
    AstraZeneca, Wilmington, DE
    Postgrad Med 126:19-32. 2014
  2. ncbi request reprint Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus and cardiovascular disease history or cardiovascular risk factors: results of a pooled analysis of phase 3 clinical trials
    William Cook
    Medical Affairs, AstraZeneca, Wilmington, DE 19850, USA
    Postgrad Med 125:145-54. 2013
  3. ncbi request reprint Saxagliptin efficacy and safety in patients with type 2 diabetes receiving concomitant statin therapy
    Brian Bryzinski
    AstraZeneca, Wilmington, DE, USA Electronic address
    J Diabetes Complications 28:887-93. 2014

Collaborators

Detail Information

Publications3

  1. ncbi request reprint Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials
    William Cook
    AstraZeneca, Wilmington, DE
    Postgrad Med 126:19-32. 2014
    ..To test the effectiveness and safety of saxagliptin 5 mg/d in patients with type 2 diabetes mellitus (T2DM) with and without history of cardiovascular disease (CVD) or cardiovascular (CV) risk factors...
  2. ncbi request reprint Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus and cardiovascular disease history or cardiovascular risk factors: results of a pooled analysis of phase 3 clinical trials
    William Cook
    Medical Affairs, AstraZeneca, Wilmington, DE 19850, USA
    Postgrad Med 125:145-54. 2013
    ..This post hoc analysis sought to assess the efficacy, safety, and tolerability of saxagliptin in patients with type 2 diabetes mellitus and cardiovascular (CV) risk factors or disease (CVD)...
  3. ncbi request reprint Saxagliptin efficacy and safety in patients with type 2 diabetes receiving concomitant statin therapy
    Brian Bryzinski
    AstraZeneca, Wilmington, DE, USA Electronic address
    J Diabetes Complications 28:887-93. 2014
    ..To examine whether concomitant statin therapy affects glycemic control with saxagliptin 2.5 and 5mg/d in patients with type 2 diabetes mellitus (T2DM)...